PD-L1 POSITIVE
Clinical trials for PD-L1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new PD-L1 POSITIVE trials appear
Sign up with your email to follow new studies for PD-L1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged attack tested for Tough-to-Treat breast cancer
Disease control Not yet recruitingThis study is testing whether a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, can help control advanced triple-negative breast cancer that has worsened after initial treatment. It will involve about 47 patients whose tumors test positive for a marker called …
Matched conditions: PD-L1 POSITIVE
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Drug attack on aggressive breast cancer
Disease control Not yet recruitingThis study is testing whether combining two drugs, sacituzumab tirumotecan and toripalimab, can help control advanced triple-negative breast cancer that has spread and cannot be removed by surgery. It will involve about 41 women who have not yet received treatment for their advan…
Matched conditions: PD-L1 POSITIVE
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC